Global human albumin market 2016-2020 - demand for albumin is high in
apac - research and markets
Dublin--(business wire)--research and markets has announced the addition of the "global human albumin market 2016-2020" report to their offering. the analysts forecast the global human albumin market to grow at a cagr of 4.97% during the period 2016-2020. the report covers the present scenario and the growth prospects of the global human albumin market for 2016-2020. to calculate the market size, the report considers revenue generated from the sales of branded and generic albumin drugs used to treat infections, liver diseases, shock, during surgery, and severe burns. the report also considers the revenues to be generated from the sales of drugs that are expected to be launched in the market along with the decline in revenues from the genericization of the marketed drugs during the forecast period. albumin-based therapies such as idelvion (csl654 rix-fp) by csl behring received marketing approval from the us fda in march 2016 and from the ema in may 2016. apart from these, albutropin (tv-1106) by teva pharmaceuticals, ampion by ampio pharmaceuticals, and albutein by grifols (for alzheimer's disease) are expected to enter the market during the forecast period. the demand for albumin is high in apac in countries like india and china. still, the uptake of these therapeutics is less due to the lack of awareness about these products and their therapeutic uses. thus, the awareness programs conducted by organizations such as ppta, which includes international plasma awareness week, to help increase the awareness about plasma donation and the different plasma protein therapies available, along with their potential uses, is expected to increase the uptake of these therapeutics in treating various conditions. key vendors - csl behring - grifols - baxalta - octapharma - kedrion other prominent vendors - aadi - ablynx - albumedix - ampio pharmaceuticals - azaya therapeutics - beijing tiantan - biotest - bristol-myers squibb - celgene - conjuchem - gsk - hebei changshan biochem pharma - himedia laboratories - hualan biological engineering - invittria - medxbio - merck - mitsubishi tanabe pharma - nantbioscience - novo nordisk - novozymes - shanghai raas blood products - sucampo pharmaceuticals - teva pharmaceuticals - thermo fisher scientific - tianjin sinobiotech & beijing bio-fortune - ventria bioscience - yoshitomi pharmaceutical key topics covered: part 01: executive summary part 02: scope of the report part 03: market research methodology part 04: introduction part 05: plasma therapeutics: an overview part 06: global plasma therapeutics market part 07: plasma fractionation market part 08: albumin: an overview part 09: pipeline portfolio part 10: global albumin market part 11: market landscape part 12: market segmentation by application part 13: geographical segmentation part 14: china albumin market part 15: market drivers part 16: impact of drivers part 17: market challenges part 18: impact of drivers and challenges part 19: market trends part 20: vendor landscape part 21: appendix for more information visit http://www.researchandmarkets.com/research/2xpnvt/global_human
PPTA Ratings Summary
PPTA Quant Ranking
You've reached your free article limit.
Want To Read More Articles?
See what it all means for your stocks with premium tools
Stockprices is a weekly video covering what moved markets
this week, featuring a panel of Stockprices editors. It is published by the
close of trading on Fridays. Hosted by Nathaniel E. Baker, contributing editor,
and featuring: Aaron Task, VP Contributor Content and co-host Stockprices's Alpha
Trader podcast; Brad Olesen, VP News; Steve Alpher, Managing Editor News, co-host
Alpha Trader.
Unsubscribe From All
You successfully activated
“Only Essentials”
Confirm Upgrade
Your subscription will be moved to the annual plan. Service will automatically renew unless cancelled. No Refunds. Click upgrade to confirm.
Stockprices uses Plaid to connect you account
Connect effortlessly
Plaid lets you securely connect your financial accounts in seconds
Your data belongs to you
Plaid doesn't sell personal info, and will only use it with your permission